Cytokinetics (CYTK) EBIAT: 2009-2025
Historic EBIAT for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to -$306.2 million.
- Cytokinetics' EBIAT fell 90.71% to -$306.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$752.0 million, marking a year-over-year decrease of 30.46%. This contributed to the annual value of -$589.5 million for FY2024, which is 12.03% down from last year.
- Per Cytokinetics' latest filing, its EBIAT stood at -$306.2 million for Q3 2025, which was down 127.86% from -$134.4 million recorded in Q2 2025.
- In the past 5 years, Cytokinetics' EBIAT ranged from a high of -$19.8 million in Q2 2022 and a low of -$306.2 million during Q3 2025.
- Over the past 3 years, Cytokinetics' median EBIAT value was -$136.9 million (recorded in 2023), while the average stood at -$156.2 million.
- Its EBIAT has fluctuated over the past 5 years, first slumped by 2,296.41% in 2021, then spiked by 67.80% in 2022.
- Cytokinetics' EBIAT (Quarterly) stood at -$30.6 million in 2021, then plummeted by 349.39% to -$137.4 million in 2022, then rose by 0.35% to -$136.9 million in 2023, then fell by 9.59% to -$150.0 million in 2024, then plummeted by 90.71% to -$306.2 million in 2025.
- Its EBIAT stands at -$306.2 million for Q3 2025, versus -$134.4 million for Q2 2025 and -$161.4 million for Q1 2025.